Who is sponsoring NCT06135584?

NCT06135584 is sponsored by The Affiliated Hospital of Hangzhou Normal University.

What drugs are being tested in NCT06135584?

Interventions in NCT06135584: Pioglitazone metformin tablets, Other drugs, Drug-free.

What condition does NCT06135584 study?

NCT06135584 studies Metabolic Dysfunction-associated Fatty Liver Disease, Cirrhosis.

Is NCT06135584 still recruiting?

NCT06135584 is currently not yet recruiting. Last updated 18 November 2023.

Last reviewed 2023-11-18 · How we verify

NCT06135584: SMART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies

Not yet recruiting NA Last updated 18 November 2023

What this trial tests

NA trial testing Pioglitazone metformin tablets in Metabolic Dysfunction-associated Fatty Liver Disease in 1,000 participants. Not yet recruiting.

Timeline

18 November 2023

Primary endpoint
31 December 2026

31 December 2026

Quick facts

Lead sponsor	The Affiliated Hospital of Hangzhou Normal University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,000
Start date	18 November 2023
Primary completion	31 December 2026
Estimated completion	31 December 2026

Drugs / interventions tested

Pioglitazone metformin tablets — full drug profile →
Other drugs — full drug profile →
Drug-free

Conditions studied

Metabolic Dysfunction-associated Fatty Liver Disease — all drugs for Metabolic Dysfunction-associated Fatty Liver Disease →
Cirrhosis — all drugs for Cirrhosis →

Sponsor

The Affiliated Hospital of Hangzhou Normal University

Who can join

Adults 18 to 75, any sex, with Metabolic Dysfunction-associated Fatty Liver Disease or Cirrhosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish a prospective, multicenter, biopsie-confirmed clinical cohort of MAFLD-related cirrhosis (F3-F4) in China, and analyze the clinical, histopathological features and natural outcomes of MAFLD-associated liver fibrosis/cirrhosis in China. And than to conducted a real-world study of different strategies of Chinese characteristics for the prevention and treatment of MAFLD-related cirrhosis to evaluate the efficacy and safety of the strategies.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.
Cazac-Panaite GD, Lăcătușu CM, Grigorescu ED, Foșălău AB, et al · · 2025 · cited 3× · PMID 40004572 · DOI 10.3390/jcm14041042
Future research direction of portal hypertension based on Baveno VII.
Luo X, Wang G, Yang L, Hernandez-Gea V. · · 2025 · PMID 40824526 · DOI 10.1097/cm9.0000000000003785

Verify or expand the search:

Other recruiting trials for Metabolic Dysfunction-associated Fatty Liver Disease

Currently open trials in the same condition.

NCT05974904 — Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study · recruiting
NCT06541132 — Positive Association of US-FLI With the Severity of CAD · recruiting

Other The Affiliated Hospital of Hangzhou Normal University trials

Trials by the same sponsor.

NCT07241195 — A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From · not yet recruiting
NCT07399600 — Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease · NA · not yet recruiting
NCT07233486 — A Multicenter, Randomized, Crossover Clinical Trial Study of Digital Intelligence Software in Patients With MAFLD · NA · recruiting
NCT06201572 — The Value of TOI in Evaluating Renal Function Damage in Hypertensive Emergency Patients · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06135584 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Hangzhou Normal University
Last refreshed: 18 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06135584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing